Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Contingent Liabilities (Details Textual)

v3.24.2.u1
Note 12 - Contingent Liabilities (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended
Feb. 29, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2023
Research and Development Expense   $ 4,879,024 $ 8,787,636 $ 9,515,865 $ 47,259,464  
Accounts Payable, Current   3,018,334 $ 15,944,004 3,018,334 $ 15,944,004 $ 12,931,172
Other Liabilities, Noncurrent   4,739,375   4,739,375   $ 29,948
Damages from Product Defects [Member]            
Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate   10,000,000        
Loss Contingency, License and Purchase Agreements [Member]            
Loss Contingency Accrual   0   0    
Loss Contingency, Commercial Dispute [Member]            
Research and Development Expense       600,000    
Loss Contingency, Commercial Dispute [Member] | Research and Development Liability [Member]            
Accounts Payable, Current   900,000   900,000    
Other Liabilities, Noncurrent   $ 4,700,000   $ 4,700,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member]            
Loss Contingency, Damages Sought, Value $ 10,000,000          
Loss Contingency Accrual, Product Liability, Net 8,300,000          
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Due Upon Execution of Agreement [Member]            
Loss Contingency Accrual, Product Liability, Net 2,300,000          
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments,One [Member]            
Loss Contingency Accrual, Product Liability, Net $ 3,500,000          
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month) 48 months          
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Balance by December 31, 2025 [Member]            
Loss Contingency Accrual, Product Liability, Net $ 2,500,000          
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments, Two [Member]            
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month) 24 months